Pulsed Focused Ultrasound Enhances MSC Kidney Homing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute kidney injury (AKI) are largely supportive and lack therapies that effectively promote kidney repair and regeneration, with mesenchymal stromal cell (MSC) therapies hindered by inefficiency in homing to damaged kidney tissue due to the pulmonary first-pass effect.
Innovation Solution
Combining pulsed focused ultrasound (pFUS) therapy with MSCs or MSC-derived extracellular vesicles for targeted kidney treatment, enhancing tissue regeneration by altering the microenvironment and improving MSC homing, along with screening methods for candidate agents that increase HSP20 or HSP40 expression, decrease HSP70 or HSP90 expression, activate PI3K/Akt signaling, or suppress NLRP3 inflammasome activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If MSCs are administered intravenously to treat kidney damage, then they can be delivered systemically, but they are trapped in the lung microvasculature due to the pulmonary first-pass effect and fail to reach the kidney
Solution Approach 1:
The patent applies preliminary action by using pFUS therapy before MSC administration to pre-condition the kidney tissue. The ultrasound treatment creates a favorable microenvironment and activates recruitment signals in the kidney prior to MSC injection, ensuring that when MSCs are administered, they are guided to the target organ rather than being trapped in the lungs.
Solution Approach 2:
The patent uses pFUS therapy as an intermediary to bridge the gap between intravenous MSC administration and kidney target delivery. The ultrasound treatment acts as a mediator that modifies the physiological environment to facilitate MSC homing to the kidney, overcoming the pulmonary first-pass barrier without changing the administration route.
2Reliability
If traditional supportive treatments are used for AKI, then they maintain blood volume and electrolyte balance, but they do not promote kidney repair and regeneration
Solution Approach 1:
The patent merges two distinct therapeutic approaches: traditional supportive care (maintaining hemodynamic stability and electrolyte balance) and regenerative medicine (MSC therapy enhanced by pFUS). This combination allows the treatment to simultaneously maintain kidney function through supportive measures while promoting tissue regeneration through the synergistic action of pFUS and MSCs.
Solution Approach 2:
The treatment protocol functions as a composite therapy combining physical modality (pFUS), biological agents (MSCs), and pharmacological support (traditional AKI management). This multi-component approach addresses both the immediate need for functional maintenance and the long-term goal of tissue regeneration.
3Productivity
If MSCs are used for kidney repair, then they provide regenerative molecules through paracrine action, but their therapeutic efficacy is limited by inefficient homing to damaged tissue
Solution Approach 1:
pFUS therapy is administered before MSC injection to pre-condition the kidney tissue and activate recruitment pathways. This preliminary treatment ensures that the kidney is ready to receive and retain MSCs, maximizing the delivery of regenerative molecules to the damaged area.
Solution Approach 2:
The patent employs pFUS to change physical parameters of the kidney tissue microenvironment, such as increasing vascular permeability and activating mechanosensitive pathways. These parameter changes create conditions that enhance MSC homing efficiency and subsequent regenerative molecule delivery to the injured tissue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances kidney tissue repair, reduces inflammation, and improves kidney function by increasing the effectiveness of MSC therapy and identifying therapeutic agents that promote regeneration and reduce inflammation.
Implementation Method 1
The methods utilize a combination of therapies, including the administration of pulsed focused ultrasound (pFUS) therapy with mesenchymal stromal cells (MSCs) and/or MSC-derived exosomes
Data Source
AI summary
Methods for treating kidney damage are provided. The methods utilize a combination of therapies, including the administration of pulsed focused ultrasound (pFUS) therapy with mesenchymal stromal cells (MSCs) and/or MSC-derived extracellular vesicles. Additionally, methods are provided for screening candidate therapeutic agents for treating kidney damage that have the ability to increase expression of HSP20 or HSP40, decrease expression of HSP70 or HSP90, enhance activation of PI3K/Akt signaling, or suppress the NLRP3 inflammasome and inflammasome-mediated inflammation.